A weekly injectable PEGylated recombinant human growth hormone gives significantly better height outcomes than no treatment in children with idiopathic short stature, shows a phase 2 trial.
Why is the growth plate the most important organ for childhood growth: how can it be investigated for clinical diagnosis?
Small-for-gestational age children should undergo regular measurements for the first 2 years after birth to help identify individuals who will benefit from recombinant human growth hormone therapy, German researchers advise.
Cardiometabolic risk in people born small for gestational age more than a decade after finishing therapy with recombinant human growth hormone is no higher than in those never given the treatment, a study shows.
Analysis of real-world data indicates that the recombinant human growth hormone somatropin is well tolerated and effective for children with a range of growth hormone disorders and other conditions associated with short stature.
A study of preterm boys shows increased androgen levels at the estimated time of birth in those with low birthweight.
Using both height and deviation from height target during growth monitoring could improve detection of pathological growth disorders in children and avoid unnecessary clinic referrals, suggest UK researchers who found the current criteria to have low sensitivity.
A systematic review and meta-analysis confirms a high rate of reversal of idiopathic growth hormone deficiency, albeit strongly dependent on the peak GH cutoff used.
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
An oral growth hormone secretagogue receptor agonist produces larger GH responses than standard stimulation tests in children with growth hormone deficiency, study findings suggest.
